823809-31-0

Basic information

• Product Name: Benzene, 1-[(1Z)-2-(4-methylphenyl)ethenyl]-2-nitro-
• CAS NO: 823809-31-0
• Molecular Formula: C15H13NO2
• Molecular Weight: 239.274
• Mol File: 823809-31-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzene, 1-[(1Z)-2-(4-methylphenyl)ethenyl]-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-[(1Z)-2-(4-methylphenyl)ethenyl]-2-nitro-(823809-31-0)
• EPA Substance Registry System: Benzene, 1-[(1Z)-2-(4-methylphenyl)ethenyl]-2-nitro-(823809-31-0)

Safety Data

• Hazardous Substances Data: 823809-31-0(Hazardous Substances Data)

Upstream product

• 104-82-5 4-Methylbenzyl chloride 
• 1530-37-6 (4-methylbenzyl)triphenylphosphonium chloride 
• 552-89-6 2-nitro-benzaldehyde 
• 2378-86-1 4-methylbenzyltriphenylphosphonium bromide 

Downstream Products

• 823809-35-4 [2-(2-p-tolyl-vinyl)-phenylamino]-acetic acid 
• 823809-33-2 (Z)-2-amino-4'-methylstilbene 

Relevant articles and documents

Complete 1H and 13C NMR spectral assignment of cis- and trans- 3-{2-[2-(4-methylphenyl)ethenyl]phenyl}sydnones

1H and 13C NMR spectra of cis- and trans-3-{2-[2-(4-methylphenyl)ethenyl]phenyl]}sydnones, the first stilbene-substituted mezoionic oxadiazolium rings, were fully assigned combining the information in various solvents, such as deuter

Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators

Anti-inflammatory effects of liver X receptor (LXR) ligands are thought to be largely due to LXR-mediated transrepression, whereas side effects are caused by activation of LXR-responsive gene expression (transactivation). Therefore, selective LXR modulators that preferentially exhibit transrepression activity should exhibit anti-inflammatory properties with fewer side effects. Here, we synthesized a series of styrylphenylphthalimide analogues and evaluated their structure-activity relationships focusing on LXRs-transactivating-agonistic/antagonistic activities and transrepressional activity. Among the compounds examined, 17l showed potent LXR-transrepressional activity with high selectivity over transactivating activity and did not show characteristic side effects of LXR-transactivating agonists in cells. This representative compound, 17l, was confirmed to have LXR-dependent transrepressional activity and to bind directly to LXRβ. Compound 17l should be useful not only as a chemical tool for studying the biological functions of LXRs transrepression but also as a candidate for a safer agent to treat inflammatory diseases.